vs

Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and TUCOWS INC (TCX). Click either name above to swap in a different company.

TUCOWS INC is the larger business by last-quarter revenue ($98.7M vs $86.8M, roughly 1.1× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 6.0%). TUCOWS INC produced more free cash flow last quarter ($-7.0M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.2%).

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.

Tucows Inc. is an American–Canadian publicly traded Internet services and telecommunications company headquartered in Toronto, Ontario, Canada, and incorporated in Pennsylvania, United States. The company is composed of three independent businesses: Tucows Domains, Ting Internet, and Wavelo.

IOVA vs TCX — Head-to-Head

Bigger by revenue
TCX
TCX
1.1× larger
TCX
$98.7M
$86.8M
IOVA
Growing faster (revenue YoY)
IOVA
IOVA
+11.8% gap
IOVA
17.7%
6.0%
TCX
More free cash flow
TCX
TCX
$54.9M more FCF
TCX
$-7.0M
$-61.9M
IOVA
Faster 2-yr revenue CAGR
IOVA
IOVA
Annualised
IOVA
1001.6%
6.2%
TCX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IOVA
IOVA
TCX
TCX
Revenue
$86.8M
$98.7M
Net Profit
$-22.0M
Gross Margin
67.4%
24.5%
Operating Margin
-84.7%
-9.1%
Net Margin
-22.3%
Revenue YoY
17.7%
6.0%
Net Profit YoY
48.1%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IOVA
IOVA
TCX
TCX
Q4 25
$86.8M
$98.7M
Q3 25
$67.5M
$98.6M
Q2 25
$60.0M
$98.5M
Q1 25
$49.3M
$94.6M
Q4 24
$73.7M
$93.1M
Q3 24
$58.6M
$92.3M
Q2 24
$31.1M
$89.4M
Q1 24
$715.0K
$87.5M
Net Profit
IOVA
IOVA
TCX
TCX
Q4 25
$-22.0M
Q3 25
$-91.3M
$-23.0M
Q2 25
$-111.7M
$-15.6M
Q1 25
$-116.2M
$-15.1M
Q4 24
$-42.5M
Q3 24
$-83.5M
$-22.3M
Q2 24
$-97.1M
$-18.6M
Q1 24
$-113.0M
$-26.5M
Gross Margin
IOVA
IOVA
TCX
TCX
Q4 25
67.4%
24.5%
Q3 25
43.0%
24.5%
Q2 25
5.5%
22.5%
Q1 25
-0.8%
24.9%
Q4 24
68.7%
23.3%
Q3 24
46.2%
24.0%
Q2 24
-0.8%
23.3%
Q1 24
20.9%
Operating Margin
IOVA
IOVA
TCX
TCX
Q4 25
-84.7%
-9.1%
Q3 25
-140.7%
-9.7%
Q2 25
-189.8%
-2.9%
Q1 25
-245.8%
-2.1%
Q4 24
-117.5%
-32.1%
Q3 24
-152.1%
-10.9%
Q2 24
-327.6%
-9.6%
Q1 24
-16464.6%
-18.9%
Net Margin
IOVA
IOVA
TCX
TCX
Q4 25
-22.3%
Q3 25
-135.3%
-23.4%
Q2 25
-186.2%
-15.9%
Q1 25
-235.5%
-16.0%
Q4 24
-45.6%
Q3 24
-142.7%
-24.2%
Q2 24
-312.2%
-20.8%
Q1 24
-15800.8%
-30.3%
EPS (diluted)
IOVA
IOVA
TCX
TCX
Q4 25
Q3 25
Q2 25
$-0.33
Q1 25
$-0.36
Q4 24
$-0.24
Q3 24
$-0.28
Q2 24
$-0.34
Q1 24
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IOVA
IOVA
TCX
TCX
Cash + ST InvestmentsLiquidity on hand
$297.0M
$46.8M
Total DebtLower is stronger
$190.4M
Stockholders' EquityBook value
$698.6M
$-164.2M
Total Assets
$913.2M
$730.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IOVA
IOVA
TCX
TCX
Q4 25
$297.0M
$46.8M
Q3 25
$300.8M
$54.1M
Q2 25
$301.2M
$52.0M
Q1 25
$359.7M
$38.1M
Q4 24
$323.8M
$56.9M
Q3 24
$397.5M
$75.2M
Q2 24
$412.5M
$39.3M
Q1 24
$356.2M
$66.6M
Total Debt
IOVA
IOVA
TCX
TCX
Q4 25
$190.4M
Q3 25
Q2 25
Q1 25
Q4 24
$195.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IOVA
IOVA
TCX
TCX
Q4 25
$698.6M
$-164.2M
Q3 25
$702.3M
$-144.1M
Q2 25
$698.5M
$-121.7M
Q1 25
$767.9M
$-108.3M
Q4 24
$710.4M
$-95.3M
Q3 24
$773.5M
$-53.1M
Q2 24
$768.5M
$-33.1M
Q1 24
$680.0M
$-15.9M
Total Assets
IOVA
IOVA
TCX
TCX
Q4 25
$913.2M
$730.9M
Q3 25
$904.9M
$735.5M
Q2 25
$907.4M
$742.2M
Q1 25
$966.7M
$741.9M
Q4 24
$910.4M
$758.8M
Q3 24
$991.1M
$799.0M
Q2 24
$964.3M
$758.2M
Q1 24
$869.8M
$780.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IOVA
IOVA
TCX
TCX
Operating Cash FlowLast quarter
$-52.6M
$-2.6M
Free Cash FlowOCF − Capex
$-61.9M
$-7.0M
FCF MarginFCF / Revenue
-71.3%
-7.1%
Capex IntensityCapex / Revenue
10.7%
4.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-336.2M
$-22.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IOVA
IOVA
TCX
TCX
Q4 25
$-52.6M
$-2.6M
Q3 25
$-78.7M
$1.5M
Q2 25
$-67.4M
$6.6M
Q1 25
$-103.7M
$-11.3M
Q4 24
$-73.3M
$-4.8M
Q3 24
$-59.0M
$-4.6M
Q2 24
$-98.4M
$-4.7M
Q1 24
$-122.3M
$-5.7M
Free Cash Flow
IOVA
IOVA
TCX
TCX
Q4 25
$-61.9M
$-7.0M
Q3 25
$-89.5M
$-2.3M
Q2 25
$-74.9M
$3.1M
Q1 25
$-109.9M
$-16.7M
Q4 24
$-77.5M
$-16.5M
Q3 24
$-61.3M
$-19.1M
Q2 24
$-98.9M
$-20.7M
Q1 24
$-126.5M
$-20.0M
FCF Margin
IOVA
IOVA
TCX
TCX
Q4 25
-71.3%
-7.1%
Q3 25
-132.7%
-2.4%
Q2 25
-124.9%
3.1%
Q1 25
-222.8%
-17.6%
Q4 24
-105.1%
-17.7%
Q3 24
-104.6%
-20.7%
Q2 24
-317.9%
-23.1%
Q1 24
-17685.3%
-22.9%
Capex Intensity
IOVA
IOVA
TCX
TCX
Q4 25
10.7%
4.4%
Q3 25
16.1%
3.9%
Q2 25
12.4%
3.5%
Q1 25
12.6%
5.7%
Q4 24
5.7%
12.5%
Q3 24
3.9%
15.7%
Q2 24
1.4%
17.8%
Q1 24
583.4%
16.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IOVA
IOVA

Amtagvi$64.9M75%
Proleukin$21.9M25%

TCX
TCX

Wholesale$57.0M58%
Fiber Internet Services$16.5M17%
Wavelo$13.0M13%
Platform Services$11.7M12%

Related Comparisons